Collegium Pharmaceutical, Inc. (COLL) Total liabilities 2016–2025
Collegium Pharmaceutical, Inc. (COLL) total liabilities at each fiscal year-end, per SEC filings.
$1.4BFY2025 · since FY2016: $27.1M → $1.4B
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $1.4B | -5.5% |
| FY2024 | $1.4B | +51.4% |
| FY2023 | $947.9M | -3.2% |
| FY2022 | $979.3M | +100.2% |
| FY2021 | $489.1M | +6.8% |
| FY2020 | $457.8M | +109.2% |
| FY2019 | $218.9M | +9.6% |
| FY2018 | $199.7M | +534.1% |
| FY2017 | $31.5M | +16.2% |
| FY2016 | $27.1M | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice
More COLL financial trends
COLL RevenueCOLL Net incomeCOLL Net marginCOLL Gross profitCOLL Gross marginCOLL Operating incomeCOLL Operating marginCOLL Operating cash flowCOLL Free cash flowCOLL Capital expendituresCOLL Return on equityCOLL Stock buybacksCOLL Dividends paidCOLL Total assetsCOLL Shareholders’ equityCOLL overview →